bioRxivBioengineeringPreprint
AI-guided design of common light chains to enable manufacturable bispecific antibodies
Longfei Cong, Brian M Richardson, Yi ZhouiD, Tong LiiD, Roger ShekiD, Yuxiang Lang, Ziwei Pang, Freddy Garces, Jarrod B. FrenchiD, Per Jr GreiseniD
Abstract
Bispecific antibodies (BsAbs) offer therapeutic advantages but face manufacturing bottlenecks from light chain mispairing, which can generate a substantial fraction of incorrect products and increase manufacturing complexity and cost of goods. Common light chains (cLC) eliminate mispairing, yet existing approaches require screening thousands of variants per target. We present an AI-driven framework that computationally designs cLCs through structure-guided pairing of non-cognate VH-VL interfaces, reducing experimental screening by three orders of magnitude. The platform successfully engineers therapeutic antibodies lacking experimental structures, expanding applicability beyond crystallographic databases. Among 10 therapeutic targets, we successfully generated designs for 7 targets, comprising 55 unique BsAb pairs. Of these, 43.6% (24/55) were successfully as BsAb cLCs. Three bispecific antibodies reached production-ready specifications: >90% purity and 1.6-1.8 g/L titers. This platform democratizes bispecific antibody development, expanding access beyond well-resourced programs.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- LegoBody: facile generation of bispecific and multi-specific antibodies
- Dual-Specific Antibody Design Using Artificial Intelligence
Michael Peer, Inbar Amit, … Yanay Ofran·bioRxiv·Aug 5, 2026
- Zero-shot antibody design in a 24-well plate
Chai Discovery Team, Jacques Boitreaud, … Kevin Wu·bioRxiv·Jul 5, 2025
- LICHEN: Light-chain Immunoglobulin sequence generation Conditioned on the Heavy chain and Experimental Needs
Henriette Capel, Isaac Ellmen, … Charlotte Mary Deane·bioRxiv·Aug 6, 2025
- Origin-1: a generative AI platform for de novo antibody design against novel epitopes
Simon Levine, Jonathan Edward King, … Amir Shanehsazzadeh·bioRxiv·May 5, 2026
- Drug-like antibody design against challenging targets with atomic precision
Chai Discovery Team, Jacques Boitreaud, … Andy Yeung·bioRxiv·Nov 29, 2025